… approved bevacizumab as a single agent for recurrent GBM … study, patients with progressive
or recurrent GBM received erlotinib (… ) showed the promising preliminary antitumor activity of …

… recurrent GBM, with a survival of 24.8 months [109], while Pembrolizumab, with or without
bevacizumab, proved ineffective in therapy… , erlotinib (targeting EGFR), bevacizumab (targeting …

… associated with small-molecule targeted therapies. Based on … , TMZ, radiotherapy, and
bevacizumab (Bev.). There are … A study in 2010 using erlotinib as monotherapy for recurrent GBM …

… the SOC treatment and targeted therapies that have been … with TMZ/radiotherapy and/or
bevacizumab (BEV, recombinant … and erlotinib was tailored to the molecular profile of the patient’…

… benefit of bevacizumab even for recurrent glioblastoma is controversial. … or do not qualify
for targeted therapies. … Preliminary analysis in the AVAglio study did not identify a predictive …

… Lastly, we discuss therapeutics for recurrent glioblastomas … novel targeted therapies that
have shown promising preliminary … approval of bevacizumab for recurrent glioblastoma in 2009. …

… future, molecular and cellular imaging approaches will more dynamically monitor the expression
of molecular … enabling more immediate adaptation of tumor-tailored, targeted therapies. …

… OS but was aimed at a preliminary assessment of regorafenib … or bevacizumab in 369 patients
with recurrent glioblastoma. … erlotinib versus TMZ or carmustine in recurrent glioblastoma: …

… targeted therapy and bevacizumab. D’alessandris et al. performed a prospective trial evaluating
erlotinib and … The authors reported a preliminary sense of efficacy and safety. As a small …

… for targeted therapies, the treatment of recurrent glioblastoma … of erlotinib with TMZ or
carmustine in 110 rGBM patients. The … bevacizumab in patients with recurrent malignant gliomas. …